Christopher Winrow, PhD, Recursion’s vice president of neuroscience, inside the company’s lab. Recursion marked a milestone in its up to $12 billion artificial intelligence (AI) collaboration with ...

On Tuesday, the AI company Recursive Superintelligence announced a $410 million compute deal with Amazon Web Services. The company, which emerged from stealth in May with $650 million in funding, is ...

Tim Rocktaschel, co-founder of Recursive Superintelligence, says his company can build recursive self-improving AI within roughly two years. Recursive Superintelligence, a London-based startup founded ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

New developments have shown positive data from the Phase 1b/2 TUPELO trial for REC-4881, designed to treat familial adenomatous polyposis, improving readings on polyp burden reduction. Cathie Wood’s ...